Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy

Pharmacotherapy

Volumn 23, Issue 2, 2003, Pages 159-164

  Carver, Peggy L ^a,c   Whang, Emily ^a   VandenBussche, Heather L ^a,c   Kauffman, Carol A ^b,d   Malani, Preeti N ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; MYCOPHENOLIC ACID;

ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTIVARIATE ANALYSIS; MYALGIA; PAIN; PARALYSIS; RISK FACTOR; SEDATION; SEX; TREATMENT OUTCOME;

EID: 0037320431     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.2.159.32078     Document Type: Article

References (13)

1. Moellering RC. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother 1999;44(suppl A):25-30.
2. Low DE. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microb Drug Resist 1995;1:223-34.
3. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000;46:347-50.
4. Rubinstein E, Prokocimer R Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999;44(suppl A):37-46.
5. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin: Synercid skin and skin structure infection group. J Antimicrob Chemother 1999:44:263-73.
6. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium: Synercid emergency-use study group. J Antimicrob Chemother 1999;44:251-61.
7. Drew RH, Perfect JR, Srinath L, Kirkimilis E, Dowzicky M, Talbot GH, for the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2000;46:775-84.
8. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-23.
9. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration [online exclusive article]. Clin Infect Dis 2001;32:e83-6. Available from www.journals.uchicago.edu/CID/journal/contents/v32n4.html. Accessed December 5, 2002.
10. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001;45:3202-4.
11. Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000;30:790-7.
12. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999;58:1061-97.
13. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999; 66:492-500.